# US 2020/0348314 A1 · Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0348314 A1
- Document ID: US20200348314A1
- Status: Published application
- Kind: A1
- Application number: 16/724,563
- Filed: 2019-12-23
- Published: 2020-11-05
- Earliest claimed: 2014-02-18
- Assignees: Cyrano Therapeutics, Inc.
- Applicants: Cyrano Therapeutics, Inc.
- Inventors: Robert I. HENKIN
- Web page: https://patentgrep.com/patent/US20200348314A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 9/0043: {Nose}
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 38/26: Glucagons
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 27/00: Drugs for disorders of the senses
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are methods for diagnosing a subject with loss and/or distortion of taste or smell, e.g., hyposmia, dysosmia, anosmia, phantosmia, hypogeusia, dysgeusia, phantogeusia, and/or ageusia. Also disclosed herein are methods and compositions for treating a subject for loss and/or distortion of taste or smell, e.g., hyposmia, dysosmia, anosmia, phantosmia, hypogeusia, dysgeusia, phantogeusia, and/or ageusia.

## Claims

### Claim at position 1

1-64. (canceled)

### Claim 65

A method comprising administering to a subject having a taste or smell disorder a PDE inhibitor or salt thereof wherein the administering is sufficient to increase a level of sonic hedgehog (SHH) in nasal mucus or saliva of the subject by at least about 10%, relative to a level of SHH prior to the administering.

### Claim 66 (depends on 65)

The method of claim 65, wherein the PDE inhibitor or salt thereof is formulated as a composition with a pH of from about 6 to about 8, wherein about is plus or minus 10%.

### Claim 67 (depends on 65)

The method of claim 65, wherein the subject is a female.

### Claim 68 (depends on 65)

The method of claim 65, wherein the administering is sufficient to decrease an H value for pyridine or thiophene, relative to an H value for pyridine or thiophene prior to the administering.

### Claim 69 (depends on 65)

The method of claim 65, wherein the administering is sufficient to increase an H value for amyl acetate or nitrobenzene, relative to an H value for amyl acetate or nitrobenzene prior to the administering.

### Claim 70 (depends on 65)

The method of claim 65, wherein the taste or smell disorder comprises hyposmia, dysosmia, anosmia, phantosmia, or a combination thereof.

### Claim 71 (depends on 65)

The method of claim 65, wherein the PDE inhibitor, or a salt thereof, is a non-selective PDE inhibitor, or a salt thereof.

### Claim 72 (depends on 65)

The method of claim 65, wherein the PDE inhibitor, or a salt thereof, is a selective PDE inhibitor, or a salt thereof.

### Claim 73 (depends on 72)

The method of claim 72, wherein the selective PDE inhibitor, or a salt thereof, is a phosphodiesterase-1 selective inhibitor, or a salt thereof; a phosphodiesterase-2 selective inhibitor, or a salt thereof; a phosphodiesterase-3 selective inhibitor, or a salt thereof; a phosphodiesterase-4 selective inhibitor, a phosphodiesterase-5 selective inhibitor, or a salt thereof, a phosphodiesterase-10 selective inhibitor, or a salt thereof; or any combination thereof.

### Claim 74 (depends on 65)

The method of claim 65, wherein the PDE inhibitor, or a salt thereof, is roflumilast, or a salt thereof; cilostazol, or a salt thereof; or any combination thereof.

### Claim 75 (depends on 65)

The method of claim 65, wherein the PDE inhibitor, or a salt thereof, is theophylline, or a salt thereof.

### Claim 76 (depends on 65)

The method of claim 65, wherein the PDE inhibitor, or a salt thereof, is administered intranasally.

### Claim 77

A method comprising:
a. measuring a level of sonic hedgehog (SHH) in a biological sample that comprises nasal mucus, saliva; or a combination thereof;
b. with the aid of a computer system comprising a computer processor and computer readable memory, identifying a subject as having a taste or smell disorder, wherein the identifying comprises:
i. comparing a level of SHH in the biological sample a threshold level stored at least transiently on the computer readable memory;
ii. detecting a lower level of SHH in the biological sample, relative to the threshold level; and
iii. communicating a presence of the taste or smell disorder based on the detecting of (ii).

### Claim 78 (depends on 77)

The method of claim 77, further comprising repeating (a) after a time period of about a week after the measuring of (a).

### Claim 79 (depends on 78)

The method of claim 78, further comprising administering a PDE inhibitor or salt thereof after the identifying of (b).

### Claim 80 (depends on 79)

The method of claim 79, further comprising monitoring the progression of treatment of the PDE inhibitor, wherein the monitoring comprises: performing the identifying of (b) after the administering over the time period of about a week, and repeating the administering if the level of SHH in the biological sample is lower than the threshold level.

### Claim 81 (depends on 80)

The method of claim 80, further comprising terminating the administering of the PDE inhibitor or salt thereof when the level of SHH is in the biological sample is at least 10% higher than the threshold level.

### Claim 82 (depends on 77)

The method of claim 77, wherein the taste or smell disorder comprises hyposmia, dysosmia, anosmia, phantosmia, or a combination thereof.

### Claim 83 (depends on 79)

The method of claim 79, wherein the PDE inhibitor, or a salt thereof, is a non-selective PDE inhibitor, or a salt thereof.

### Claim 84 (depends on 79)

The method of claim 79, wherein the PDE inhibitor, or a salt thereof, is a selective PDE inhibitor, or a salt thereof.

### Claim 85 (depends on 84)

The method of claim 84, wherein the selective PDE inhibitor, or a salt thereof, is a phosphodiesterase-1 selective inhibitor, or a salt thereof; a phosphodiesterase-2 selective inhibitor, or a salt thereof; a phosphodiesterase-3 selective inhibitor, or a salt thereof; a phosphodiesterase-4 selective inhibitor, a phosphodiesterase-5 selective inhibitor, or a salt thereof, a phosphodiesterase-10 selective inhibitor, or a salt thereof; or any combination thereof.

### Claim 86 (depends on 79)

The method of claim 79, wherein the PDE inhibitor, or a salt thereof, is roflumilast, or a salt thereof; cilostazol, or a salt thereof; or any combination thereof.

### Claim 87 (depends on 79)

The method of claim 79, wherein the PDE inhibitor, or a salt thereof, is theophylline, or a salt thereof.
